NCT04687137 - Expanded Access Program With Lanadelumab for Japanese People With Hereditary Angioedema | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 10, 2021

Primary Completion Date

June 18, 2022

Study Completion Date

June 18, 2022

Conditions

Hereditary Angioedema

Interventions

DRUG

TAK-743 300 mg

TAK-743 300 mg, subcutaneous injection every 2 or 4 weeks

Trial Locations (9)

Toyohashi Municipal Hospital, Toyohashi

Asahi General Hospital, Asahi

Tomakomai City Hospital, Tomakomai

Kobe University Hospital, Kobe

Tokai University Hospital, Isehara

Yokohama City University Hospital, Yokohama

Osaka University Hospital, Suita

Saiyu Soka Hospital, Sōka

Hiroshima University Hospital, Hiroshima